- Home
- CSCI
CSCI
COSCIENS BIOPHARMA INC
as 04-03-2025 4:00pm EST
Stocks
| Founded: | 1990 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 61.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.96 - $11.10 | Next Earning Date: | 05-13-2025 |
| Revenue: | $4,834,000 | Revenue Growth: | -25.23% |
| Revenue Growth (this year): | -2.49% | Revenue Growth (next year): | N/A |
Latest COSCIENS BIOPHARMA INC News
CSCI Breaking Stock News: Dive into CSCI Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
Newsfile
15 days ago
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
GlobeNewswire
22 days ago
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
GlobeNewswire
3 months ago
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
Simply Wall St.
5 months ago
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)
GlobeNewswire
5 months ago
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
GlobeNewswire
6 months ago
COSCIENS Biopharma Announces Change to Board of Directors
GlobeNewswire
6 months ago
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
Compare CSCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSCI COSCIENS BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.